RxDoctor Payments Data

David Rosvold, MD

Cardiovascular Disease · Robbinsville, NJNPI 1275500852

Payments from drug & device makers

$1,421in general payments, 2019–2025

Across 88 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$264
  • Novartis$183
  • E.r. Squibb & Sons, L.L.C.$151
  • Amgen$135
  • Edwards Lifesciences$134
  • Boston Scientific$73
  • plus $481 from 12 others

What the payments were for

  • Food & beverage$1,40899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,421 in reported general payments places this provider in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$162,557
Medicare patients
654
Services billed
2,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban459$554,112
XareltoRivaroxaban285$319,585
Repatha SureclickEvolocumab161$165,459
EntrestoSacubitril/Valsartan58$85,420
MultaqDronedarone Hcl43$51,218
FarxigaDapagliflozin Propanediol37$40,786
Praluent PenAlirocumab45$35,328
Icosapent Ethyl51$32,988
VascepaIcosapent Ethyl29$24,855
BrilintaTicagrelor25$23,290
Metoprolol Succinate1,043$16,182
Rosuvastatin Calcium1,172$15,729
Valsartan284$10,324
Carvedilol ErCarvedilol Phosphate17$10,149
LivaloPitavastatin Calcium15$9,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$554,112459 claims
Johnson & JohnsonXarelto$264$319,585285 claims
NovartisEntresto$183$85,42058 claims
AstraZenecaFarxiga, Brilinta$71$64,07662 claims
Sanofi-aventis U.S. LLCMultaq$14$51,21843 claims
Kowa Pharmaceuticals America, Inc.Livalo$43$9,49415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Robbinsville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →